Safety and Trough Concentrations of Nevirapine Prophylaxis Given Daily, Twice Weekly, or Weekly in Breast-Feeding Infants from Birth to 6 Months

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue 5, 2003, Pages 482-490

  Shetty, Avinash K ^a,b,k   Coovadia, Hoosen M ^c   Mirochnick, Mark M ^d   Maldonado, Yvonne ^a   Mofenson, Lynne M ^e   Eshleman, Susan H ^f   Fleming, Thomas ^g,h   Emel, Lynda ^g   George, Kathy ⁱ   Katzenstein, David A ^a   Wells, Jennifer ^b   Maponga, Charles C ^b   Mwatha, Anthony ^g   Jones, Samuel Adeniyi ^j   Karim, Salim S Abdool ^c   Bassett, Mary T ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f DEPARTMENT OF PATHOLOGY   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ FAMILY HEALTH INTERNATIONAL   (United States)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^k WAKE FOREST SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Clinical trial; HIV 1; Infant; Nevirapine; Pregnancy; Prophylaxis; Safety

Indexed keywords

ANTIRETROVIRUS AGENT; NEVIRAPINE;

ANEMIA; ARTICLE; BREAST FEEDING; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFANT NUTRITION; MAJOR CLINICAL STUDY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTI-HIV AGENTS; BREAST FEEDING; EPIDEMIOLOGIC RESEARCH DESIGN; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MATERNAL AGE; METABOLIC CLEARANCE RATE; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SAFETY; SOUTH AFRICA; TIME FACTORS; ZIMBABWE;

EID: 0345059380     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200312150-00006     Document Type: Article

References (37)

1. Mofenson LM, McIntyre JA. Advances and research directions in the prevention of mother-to-child HIV-1 transmission. Lancet. 2000;355:2237-2244.
2. Smith MM, Kuhn L. Exclusive breastfeeding: does it have potential to reduce breastfeeding transmission of HIV-1? Nutr Rev. 2000;58:333-340.
3. Coovadia HM, Coutsoudis A. Problems and advances in reducing transmission of HIV-1 through breastfeeding in developing countries. AIDScience. 2001;1:1-10. Available at: http://aidsscience.com/Articles/aidscience004. htm.
4. American Academy of Pediatrics Work Group on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics. 1997;100:1035-1039.
5. Humphrey J, Iliff P. Is breast not the best? Feeding babies born to HIV-positive mothers: bringing balance to a complex issue. Nutr Rev. 2000;59:119-127.
6. Coutsoudis A. Promotion of exclusive breastfeeding in the face of the HIV pandemic. Lancet. 2000;356:1620-1621.
7. Nduati R. Breastfeeding and HIV-1 infection: a review of current literature. In: Kolezko B, Michaelsen KF, Hernell O, eds. Short and Long Term Effects of Breast Feeding on Child Health. Kluwer Academic/Plenum Publishers; Dordrecht, The Netherlands, 2000;31-37.
8. Dunn DT, Newell ML, Ades AE, et al. Risk of human immunodeficiency virus type I transmission through breastfeeding. Lancet. 1992;340:585-588.
9. Tess BH, Rodrigues LC, Newell ML, et al. Breastfeeding, genetic, obstetric and other risk factors associated with mother-to-child transmission of HIV-1 in Sao Paulo State, Brazil. AIDS. 1998; 12:513-520.
10. Bobat R, Moodley D, Coutsoudis A, et al. Breastfeeding by HIV-1 infected women and outcome in their infants: a cohort study from Durban, South Africa. AIDS. 1997;11:1627-1633.
11. Miotti PG, Taha TET, Kumwenda NI, et al. HIV transmission through breastfeeding: a study in Malawi. JAMA. 1999;282:744-749.
12. Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized controlled trial. JAMA. 2000;283:1167-1174.
13. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795-802.
14. Mofenson LM. Short-course zidovudine for prevention of perinatal infection. Lancet. 1999;353:766-767.
15. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomized trial. Lancet. 1999;352:781-785.
16. Dabis F, Msellati P, Meda N, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of zidovudine to reduce vertical transmission of HIV-1 in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicenter trial. Lancet. 1999;353:786-792.
17. The Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomized, double-blind, placebo-controlled trial. Lancet. 2002;359: 1178-1186.
18. Leroy V, Karon JM, Alioum A, et al. Twenty-four month efficacy of a maternal short-course zidovudine regimen to prevent mother-to-child transmission of HIV-1 in West Africa. AIDS. 2002;16:631-641.
19. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother to child transmission of HIV-1 in Kampala, Uganda: 18 months follow-up of the HIVNET 012 randomised trial. Lancet. 2003;362:859-868.
20. Bardsley-Elliot A, Perry CM. Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection. Paediatr Drugs. 2000; 5:373-407.
21. Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. J Infect Dis. 1998;178:368-374.
22. Musoke P, Guay L, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-infected Ugandan women and their neonates (HIVNET 006). AIDS. 1999;13:479-486.
23. Dorenbaum A, Cunningham C, Gelber RD, et al. European Collaborative Study for the International PACTG 316 Team. Addition of two-dose intrapartum/newbom nevirapine to standard antiretroviral therapy to reduce perinatal human immunodeficiency virus type-1 transmission: Pediatric AIDS Clinical Trials Group 316. JAMA. 2002;288:189-198.
24. UNAIDS. HIV and Infant Feeding: Guidelines for Decision-Makers. UNAIDS/WHO Joint United Nations Program on HIV/AIDS. Geneva: WHO; 1998.
25. Riska P, Lamson M, MacGregor T, et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos. 1999;27:895-901.
26. Lamson MJ, Cort S, Sabo JP, et al. Effects of gender on the single and multiple dose pharmacokinetics of nevirapine 200 mg/day [abstract]. Presented at the XI International Conference on AIDS, Vancouver, July 1996.
27. Pav JW, Rowland LS, Korpalski DJ. HPLC-UV method for the quantification of nevirapine in biological matrices following solid phase extraction. J Pharm Biomed Anal. 1999;20:91-98.
28. Murphy RL, Montaner JL. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs. 1996;5:1183-1189.
29. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 2003; 187:725-735.
30. Taha TE, Kumwenda N, Gibbons A, et al. Effect of HIV antiretroviral prophylaxis on hepatic and hematologic parameters of African infants. AIDS. 2002;16:851-858.
31. Englund J, Baker C, Raskino C, et al, for the Pediatric AIDS Clinical Trials Group (ACTG) Study 152 Team. Zidovudine, didanosine or both as the initial treatment for symptomatic HIV-infected children. N Engl J Med. 1997;336:1704-1712.
32. Mukiibi JM, Nkrumah FK, Kaur M, et al. Neonatal hematology in Zimbabwe. II: the red cell and white cell parameters. Centr Afr J Med. 1995; 41:76-82.
33. Scott-Emuakpor AB, Okolo AA, Omene JA, et al. Pattern of leukocytes in the blood of healthy African neonates. Acta Haematol. 1985;74:104-107.
34. Sadowitz PO, Oski FA. Differences in polymorphonuclear cell counts between healthy white and black infants: response to meningitis. Pediatrics. 1983;72:405-407.
35. Reed WW, Diehl LF. Leukopenia, neutropenia, and reduced hemoglobin levels in healthy American blacks. Arch Intern Med. 1991;151:501-505.
36. Scott-Emuakpor AB, Okolo AA, Omene JA, et al. Normal hematological values of the African neonate. Blut. 1985;51:11-18.
37. Haddy TB, Rana SR, Castro O. Benign ethnic neutropenia: what is a normal absolute neutrophil count? J Lab Clin Med. 1999;133:15-22.